RVTY

Revvity announced the launch of Signals LabGistics, an AI-first software solution designed to connect and orchestrate scientific workflows across pharmaceutical, biotechnology, and specialty chemical companies. The platform converts natural-language instructions into coordinated workflows, integrates with existing lab systems, and will be available in major markets by December 2026. The announcement follows Revvity's recent acquisitions and product launches in diabetes screening and cell models.

Revvity (RVTY), a maker of scientific instruments, has been upgraded to Zacks Rank #2 (Buy) due to rising earnings estimate revisions over the past three months. The upgrade reflects positive momentum in the company's earnings outlook, which historically correlates with near-term stock price increases. The company is expected to earn $5.36 per share for fiscal year 2026.

Revvity (RVTY) is rated a Hold with strong growth potential across diagnostics, life sciences, and scientific informatics. The company benefits from AI-driven demand, the planned Human Cell Design acquisition, and solid diagnostics growth (11% organic revenue increase in Q2).

However, challenges include China divestiture uncertainty, uneven academic funding, and margin pressure from non-recurring tariff benefits. The stock has outperformed the broader market with a 56.1% year-to-date gain.